Verastem, Inc. (NASDAQ:VSTM) saw strong trading volume on Wednesday . 20,816,365 shares traded hands during trading, an increase of 2,043% from the previous session’s volume of 971,464 shares.The stock last traded at $4.92 and had previously closed at $3.84.

Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated a “hold” rating and set a $2.00 target price on shares of Verastem in a report on Thursday, May 11th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price (up from $6.50) on shares of Verastem in a report on Thursday. Zacks Investment Research upgraded shares of Verastem from a “sell” rating to a “hold” rating in a report on Thursday, May 25th. Cann reiterated a “buy” rating and set a $2.00 target price on shares of Verastem in a report on Thursday, May 11th. Finally, Oppenheimer Holdings, Inc. set a $6.00 target price on shares of Verastem and gave the company a “buy” rating in a report on Sunday, June 4th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $5.04.

The stock’s market capitalization is $182.74 million. The firm has a 50-day moving average price of $3.58 and a 200 day moving average price of $2.46.

Verastem (NASDAQ:VSTM) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.02. Equities research analysts anticipate that Verastem, Inc. will post ($1.38) earnings per share for the current year.

A number of large investors have recently bought and sold shares of VSTM. TFS Capital LLC purchased a new stake in Verastem during the first quarter valued at approximately $113,000. Renaissance Technologies LLC lifted its position in Verastem by 20.0% during the first quarter. Renaissance Technologies LLC now owns 1,226,600 shares of the biopharmaceutical company’s stock valued at $2,539,000 after acquiring an additional 204,400 shares during the last quarter. Howland Capital Management LLC lifted its position in Verastem by 16.5% during the second quarter. Howland Capital Management LLC now owns 294,007 shares of the biopharmaceutical company’s stock valued at $641,000 after acquiring an additional 41,616 shares during the last quarter. Alpine Woods Capital Investors LLC purchased a new stake in Verastem during the second quarter valued at approximately $109,000. Finally, Artal Group S.A. purchased a new stake in Verastem during the second quarter valued at approximately $1,090,000. 24.19% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/09/08/verastem-inc-vstm-sees-large-volume-increase.html.

About Verastem

Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.